SAHPRA alerts all healthcare professionals about the risk of serious heart problems, seizures, coma and death associated with the use of high doses of diphenhydramine- containing medicines. The South African Health Products Regulatory Authority (SAHPRA) wishes to alert healthcare professionals about the risk of serious heart...
20 October 2020 SAHPRA refutes claims made by the Black Farmers Association of South Africa (BFASA) that SAHPRA is a corrupt entity with an inclination towards White bias, in the issuing of licenses, generally and particularly with respect to cannabis products. SAHPRA is subject to inter...
The South African Health Products Regulatory Authority (SAHPRA), in collaboration with other regulatory agencies, are reviewing the final pharmaceutical products for immediate and extended release dosage forms containing metformin hydrochloride as an active substance. This review was triggered because of the detection of an impurity,...
The South African Health Products Regulatory Authority (SAHPRA), in collaboration with other regulatory agencies, are reviewing all ranitidine-containing medicines with the following Active Pharmaceutical Ingredient; ranitidine. SAHPRA previously issued a media release regarding the recall and quarantine of ranitidine containing medicines (29 October 2019 and...
On 01 October 2020, the Pretoria High Court delivered its judgment in the matter between the Alliance of Natural Health Products in South Africa (“ANHP”) v Minister of Health and SAHPRA. In the application ANHP sought to review and have set aside certain aspects of...
Embargo: Immediate release SAHPRA has issued Section 21 authorisation for one serological test kit (rapid, point of care test kit) and five lab-based SARS-Cov-2 serology tests. For the rapid, point of care serology tests, the manufacturer is Zhejiang Orient Gene Biotech. There are seven licence holders for...
In the interest of public health, SAHPRA has launched the COVI-Vig reporting system for vigilanceand monitoring of health products being used for prevention or treatment of COVID-19 outside ofa clinical trial and outside of the MEURI framework. Under these circumstances, we are aware that a number...
The Backlog Clearance Programme has received applications for Re-submission Windows 1 to 9. The quality of submissions has improved significantly. We are receiving all applications submitted on the Document Uploading System via the FTP site and all queries from applicants regarding the FTP site are...
Business-As-Usual (BAU) process have been amended to be in line with new regulatory processes emanating from the Backlog Clearance Programme (BCP) pilot lessons and findings. BAU applications are those applications received by SAHPRA from 1st February 2018. This includes variation applications received from 1st February 2018, which...
In its 25 November 2019 communication to stakeholders about cannabis and related substances, SAHPRA drew attention to the 18 September 2018 decision of the Constitutional Court, which found sections of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) (the “Medicines and Related...
